Use of the basophil activation test in monitoring clinical tolerance after desensitization to brentuximab vedotin

Brentuximab vedotin is a monoclonal antibody-drug conjugate directed against the protein CD301. Brentuximab vedotin is indicated for treating patients with CD30+ Hodgkin lymphoma (HL) for which treatment with autologous stem cell transplant (ASCT) or 2 previous chemotherapy treatments have failed and when ASCT or chemotherapy are contraindicated.1

http://ift.tt/2qNhsct